A new medication found to reduce the chance of the most common types of breast cancer recurring will be available to many ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

In a large Chinese trial presented at the American Society of Clinical Oncology annual meeting, neoadjuvant therapy with a ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

Patients with certain subtypes of breast cancer may be at higher risk for death by waiting more than 42 days after their ...

A potentially life-saving treatment for early-stage breast cancer will become much more affordable for hundreds of ...

DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2-low ...

Ananda Lewis chose alternative breast cancer treatments for years before her death this month. Here’s what she tried and what ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...